Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Emergent BioSolutions news
29.04.2022
The loss of Emergent BioSolutions under GAAP for the 3 months of 2022 was $3.7 million, compared to a profit of $69.7 million in the previous year. Revenue decreased 10.3% to $307.5 million from $343 million a year earlier.
Source: 
sec.gov
sec.gov
25.02.2022
Emergent BioSolutions' GAAP net income for 2021 was $230.9 million, down 24.3% from $305.1 million in the previous year. Revenue increased 15.3% to $1.793 billion from $1.555 billion a year earlier.
Source: sec.gov
sec.gov
05.11.2021
Emergent BioSolutions reported a GAAP net profit of $41.6 million for 9M 2021, down 2.9x from $119.7 million in the previous year. Revenue increased 10.1% to $1.07 billion from $0.972 billion a year earlier.
investors.emergentbiosolutions.com
30.07.2021
Emergent BioSolutions reported GAAP net income of $74.3 million for the six months ended December 31, 2021, down 7.4% from $80.2 million in the prior year. Revenue increased 26.1% to $740.5 million from $587.2 million a year earlier.
General information
| Company name | Emergent BioSolutions |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200 |
| Mailing address | 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 |
| Website | www.emergentbiosolutions.com |
| Information disclosure | www.sec.gov |
English (US) 